Zepbound raked in $4.3 billion in the fourth quarter, which was up 123% year over year and an increase from $3.6 billion in the third quarter and, Yee noted, the drug continues to show robust growth despite compounded injectable GLP-1 Wegovy. Lilly is projecting 2026 sales to come in at between $80 billion and $83 billion, Fierce Pharma reported this week
With insurance coverage varying significantly and Medicare not covering weight loss medications, many patients explore cash-pay alternatives through various access pathways
However, it is worth noting that it has a complicated setup with multiple units, like vial unscrambling, ultrasonic washing, depyrogenation tunnel, filling, and stoppering
Drowsiness after injection is a normal and expected response
Some research suggests that its effects can mimic those of certain diabetes medications by improving insulin sensitivity and lowering fasting glucose levels